ERBB2 and hematologic disorder: Several cases of this phenomenon have been reported, the most notorious and fatal one occurred during the early development of anti-HER2 CAR-T, where the recognition of lung ERBB2+ epithelial cells by the infused cells caused massive cytokine release resulting in patient death [12] Of note, while in hematological malignancies several therapies allowing for the replenishment of immune cells can help in managing normal cells toxicity, it is difficult to contain healthy tissues damage in solid tumors.